
PROTEIN C CONCENTRATE (HUMAN)
| PROTEIN C CONCENTRATE (HUMAN) (pro'teen) Ceprotin Classifications: anticoagulant; protein inhibitor ; Therapeutic: anticoagulant; thrombolytic; protein c replacement therapy Pregnancy Category: C |
Availability
500 unit, 1000 unit vials of lyophilized powder
Action
Protein C is a critical element in a pathway that provides a natural mechanism for control of the coagulation system. The pathway prevents excess procoagulant responses to activating stimuli.
Therapeutic Effect
Protein C is necessary to decrease thrombin generation and intravascular clot formation.
Uses
Treatment of patients with severe congenital protein C deficiency; protein C replacement therapy for the prevention and treatment of venous thrombosis and purpura fulminans in children and adults.
Contraindications
Hypersensitivity to human protein C; concurrent administration with tissue plasminogen activator (tPA); hypernatremia; pregnancy (category C); lactation.
Cautious Use
Concurrent administration of anticoagulants; heparin induced thrombocytopenia (HIT); renal impairment; hepatic impairment; older adults.
Route & Dosage
| Acute Episodes of Venous Thrombosis and Purpura Fulminans and Short-Term Prophylaxis Adult: IV Initial dose 100120 units/kg; then 6080 units/kg q6h x 3. Maintenance dose: 4560 units/kg q612h. |
Administration
| Intravenous ADMINISTER: Direct/IV Infusion: • Bring powder and supplied diluent to room temperature. Insert supplied double-ended transfer needle into diluent vial, then invert and rapidly insert into protein C powder vial. (If vacuum does not draw diluent into vial, discard.) Remove transfer needle and gently swirl to dissolve. • Resulting solution concentration is 100 units/mL and it should be colorless to slightly yellowish, clear to slightly opalescent and free from visible particles. • Withdraw required dose with the supplied filter needle. ADMINISTER: Direct/IV Infusion: Infuse at 2 mL/min. Direct/IV Infusion for Child >10 kg: Infuse at 0.2 mL/kg/min. |
- Store at room temperature for no more than 3 h after reconstitution. Prior to reconstitution, protect from light.
Adverse Effects (≥1%)
Body as a Whole: Fever, hyperhidrosis, hypersensitivity reactions (rash, pruritits), restlessness. CNS: Lightheadedness. CV: Hemothorax, hypotension.Interactions
Drug: Protein C concentrate can increase bleeding caused by alteplase, reteplase, or tenecteplase.Pharmacokinetics
Peak: 0.51 h. Half-Life: 9.9 h.Nursing Implications
Assessment & Drug Effects
- Monitor for and promptly report S&S of bleeding or hypersensitivity reactions (see Appendix F).
- Monitor vital signs including BP and temperature.
- Lab tests: Baseline and periodic protein C activity, protein C trough level with acute thrombotic events; platelet counts; frequent serum sodium with renal function impairment.
Patient & Family Education
- Report immediately early signs of hypersensitivity reactions including hives, generalized itching, tightness in chest, wheezing, difficulty breathing.
- Report immediately any signs of bleeding including black tarry stools, pink/red-tinged urine, unusual bruising.
Canadian drug name;
Prototype drug